To investigate the impact of PTPRD/PTPRT mutations on the efficacy of ICIs, genomic and clinical data on samples obtained from 1,556 pan-cancer patients treated with ICIs, including anti-PD-(L)1 monotherapy, anti-CTLA-4 monotherapy and anti-PD-(L)1 in combination with anti-CTLA-4 therapy, were retrieved from the cBioportal. This evidence concerns the gene PTPRT and cancer.